Collaboration

BioInnovation Institute Foundation (BII) and Ferring Pharmaceuticals have expanded their collaboration with the objective to accelerate world-class life science innovation within women’s health. New activities will include supporting BII to source and potentially fund and incubate early-stage start-ups and projects within the field of reproductive medicine. “The new strategic collaboration, highlights Ferring’s continued commitment to […]

Scientists at The Institute of Cancer Research, London, are teaming up with small molecule neoantigen immuno-oncology company NeoPhore to develop new potential cancer drugs. Under a new strategic research collaboration, an ICR team led by Professor Chris Lord will investigate the effect of NeoPhore’s inhibitors on tumours in the laboratory. The inhibitors are small molecules […]

Cancer research has always been a team sport. But as cancer science delves ever deeper into chemistry, physics, data science, basic biology, and immunology, all these disciplines need to collaborate to bridge traditional boundaries more effectively, according to the AACR President. “This is an old story with new components. We all need to think much […]

LyGenesis and Imagine Pharma have entered into a joint research collaboration to develop novel cell therapies for patients with type 1 diabetes. The research collaboration will use Imagine Pharma’s Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) and LyGenesis’ allogeneic cell therapy platform to develop therapies for type 1 diabetes. Type 1 diabetes affects […]

Italian research institute and contract research organisation IRBM has become the only company from outside the United States to join cancer drug discovery network the Chemical Biology Consortium (CBC). The CBC is the discovery engine of the National Cancer Institute (NCI) Experimental Therapeutics (NExT) Program, administered through the Frederick National Laboratory for Cancer Research (FNLCR), […]

Companies Evergreen Discovery and Orbit Discovery have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals. The agreement covers activities including designing peptide libraries, hit identification and hit validation to confirm cell surface binding properties. The radiopharmaceuticals market is rapidly expanding with the development of a variety […]

Galapagos and NovAliX have entered a strategic collaboration in which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred to NovAliX, a drug discovery-focused Contract Research Organisation. The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology, and the strategic reorientation of the […]

Astellas Pharma and MIMETAS, which specialises in human disease modelling, have entered a strategic partnership to develop treatments for cancer. The companies will use MIMETAS’ tumour models to support the next generation of immuno-oncological therapies. “We are excited to make this next step in our longstanding collaboration with Astellas,” Paul Vulto, CEO of MIMETAS, said. […]

Sonoma Biotherapeutics and Regeneron Pharmaceuticals have announced plans to collaborate on the discovery, development and commercialisation of novel regulatory T cell (Treg) therapies for autoimmune diseases. The collaboration will bring together Regeneron’s VelociSuite technologies for the discovery and characterisation of fully human antibodies and T cell receptors (TCRs) with Sonoma Biotherapeutics’ approach to developing and […]

Merck has bought the exclusive worldwide rights to develop, manufacture and commercialise anti PD-L1 antibody Bavencio (avelumab) from Pfizer. Merck will take full control of the global commercialisation of Bavencio through its affiliate Ares Trading. The transaction has also ended a long-term collaboration between Merck and Pfizer. The current profit share will be replaced by […]